6	CD	6	6	6	N	O
ADVERSE	JJ	adverse	adverse	advers	N	O
REACTIONS	NN	reactions	reaction	reaction	N	O

The	DT	the	the	the	N	O
following	JJ	following	following	follow	N	O
adverse	JJ	adverse	adverse	advers	N	O
reaction	NN	reaction	reaction	reaction	N	O
is	VBZ	is	is	is	N	O
discussed	VBN	discussed	discussed	discuss	N	O
in	IN	in	in	in	N	O
greater	JJR	greater	greater	greater	N	O
detail	NN	detail	detail	detail	N	O
in	IN	in	in	in	N	O
other	JJ	other	other	other	N	O
sections	NNS	sections	section	section	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
label	NN	label	label	label	N	O
:	:	:	:	:	N	O

Transaminase	NNP	transaminase	transaminase	transaminas	N	B-AdverseReaction
Elevations	NNP	elevations	elevation	elev	N	I-AdverseReaction
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Warnings	NNP	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.1	CD	5.1	5.1	5.1	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O

EXCERPT	NN	excerpt	excerpt	excerpt	N	O
:	:	:	:	:	N	O
The	DT	the	the	the	N	O
most	RBS	most	most	most	N	O
common	JJ	common	common	common	N	O
adverse	JJ	adverse	adverse	advers	N	O
drug	NN	drug	drug	drug	N	O
reactions	NNS	reactions	reaction	reaction	N	O
to	TO	to	to	to	N	O
KALYDECO	NNP	kalydeco	kalydeco	kalydeco	N	O
(	(	(	(	(	N	O
occurring	VBG	occurring	occurring	occur	N	O
in	IN	in	in	in	N	O
8%	CD	8%	8%	8%	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
CF	NNP	cf	cf	cf	N	O
who	WP	who	who	who	N	O
have	VBP	have	have	have	N	O
a	DT	a	a	a	N	O
G551D	NNP	g551d	g551d	g551d	N	O
mutation	NN	mutation	mutation	mutat	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
CFTR	NNP	cftr	cftr	cftr	N	O
gene	NN	gene	gene	gene	N	O
)	)	)	)	)	N	O
were	VBD	were	were	were	N	O
headache	NN	headache	headache	headach	Y	B-AdverseReaction
,	,	,	,	,	N	O
oropharyngeal	JJ	oropharyngeal	oropharyngeal	oropharyng	N	B-AdverseReaction
pain	NN	pain	pain	pain	Y	I-AdverseReaction
,	,	,	,	,	N	O
upper	JJ	upper	upper	upper	N	B-AdverseReaction
respiratory	NN	respiratory	respiratory	respiratori	N	I-AdverseReaction
tract	NN	tract	tract	tract	N	I-AdverseReaction
infection	NN	infection	infection	infect	Y	I-AdverseReaction
,	,	,	,	,	N	O
nasal	JJ	nasal	nasal	nasal	N	B-AdverseReaction
congestion	NN	congestion	congestion	congest	N	I-AdverseReaction
,	,	,	,	,	N	O
abdominal	JJ	abdominal	abdominal	abdomin	N	B-AdverseReaction
pain	NN	pain	pain	pain	Y	I-AdverseReaction
,	,	,	,	,	N	O
nasopharyngitis	NN	nasopharyngitis	nasopharyngitis	nasopharyng	Y	B-AdverseReaction
,	,	,	,	,	N	O
diarrhea	NN	diarrhea	diarrhea	diarrhea	Y	B-AdverseReaction
,	,	,	,	,	N	O
rash	NN	rash	rash	rash	Y	B-AdverseReaction
,	,	,	,	,	N	O
nausea	NN	nausea	nausea	nausea	Y	B-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
dizziness	NN	dizziness	dizziness	dizzi	Y	B-AdverseReaction
.	.	.	.	.	N	O

(	(	(	(	(	N	O
6.1	CD	6.1	6.1	6.1	N	O
)	)	)	)	)	N	O

To	TO	to	to	to	N	O

report	NN	report	report	report	N	O
SUSPECTED	NNP	suspected	suspected	suspect	N	O
ADVERSE	NNP	adverse	adverse	advers	N	O
REACTIONS	NNP	reactions	reaction	reaction	N	O
,	,	,	,	,	N	O
contact	NN	contact	contact	contact	N	O
Vertex	NNP	vertex	vertex	vertex	N	O
Pharmaceuticals	NNP	pharmaceuticals	pharmaceutical	pharmaceut	N	O
Incorporated	NNP	incorporated	incorporated	incorpor	N	O
at	IN	at	at	at	N	O
1	CD	1	1	1	N	O
-	:	-	-	-	N	O
877	CD	877	877	877	N	O
-	:	-	-	-	N	O
634	CD	634	634	634	N	O
-	:	-	-	-	N	O
8789	CD	8789	8789	8789	N	O
or	CC	or	or	or	N	O
FDA	NNP	fda	fda	fda	N	O
at	IN	at	at	at	N	O
1	CD	1	1	1	N	O
-	:	-	-	-	N	O
800	CD	800	800	800	N	O
-	:	-	-	-	N	O
FDA	NNP	fda	fda	fda	N	O
-	:	-	-	-	N	O
1088	CD	1088	1088	1088	N	O
or	CC	or	or	or	N	O
www	VB	www	www	www	N	O
.	.	.	.	.	N	O
fda	NN	fda	fda	fda	N	O
.	.	.	.	.	N	O
gov	JJ	gov	gov	gov	N	O
medwatch	NN	medwatch	medwatch	medwatch	N	O
.	.	.	.	.	N	O

6.1	CD	6.1	6.1	6.1	N	O

Clinical	JJ	clinical	clinical	clinic	N	O
Trials	NNS	trials	trial	trial	N	O
Experience	NN	experience	experience	experi	N	O

Because	IN	because	because	becaus	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
are	VBP	are	are	are	N	O
conducted	VBN	conducted	conducted	conduct	N	O
under	IN	under	under	under	N	O
widely	RB	widely	widely	wide	N	O
varying	VBG	varying	varying	vari	N	O
conditions	NNS	conditions	condition	condit	N	O
,	,	,	,	,	N	O
adverse	JJ	adverse	adverse	advers	N	O
reaction	NN	reaction	reaction	reaction	N	O
rates	NNS	rates	rate	rate	N	O
observed	VBD	observed	observed	observ	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
of	IN	of	of	of	N	O
a	DT	a	a	a	N	O
drug	NN	drug	drug	drug	N	O
cannot	NN	cannot	cannot	cannot	N	O
be	VB	be	be	be	N	O
directly	RB	directly	directly	directli	N	O
compared	VBN	compared	compared	compar	N	O
to	TO	to	to	to	N	O
rates	NNS	rates	rate	rate	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
of	IN	of	of	of	N	O
another	DT	another	another	anoth	N	O
drug	NN	drug	drug	drug	N	O
and	CC	and	and	and	N	O
may	MD	may	may	may	N	O
not	RB	not	not	not	N	O
reflect	VB	reflect	reflect	reflect	N	O
the	DT	the	the	the	N	O
rates	NNS	rates	rate	rate	N	O
observed	VBD	observed	observed	observ	N	O
in	IN	in	in	in	N	O
clinical	JJ	clinical	clinical	clinic	N	O
practice	NN	practice	practice	practic	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
overall	JJ	overall	overall	overal	N	O
safety	NN	safety	safety	safeti	N	O
profile	NN	profile	profile	profil	N	O
of	IN	of	of	of	N	O
KALYDECO	NNP	kalydeco	kalydeco	kalydeco	N	O
is	VBZ	is	is	is	N	O
based	VBN	based	based	base	N	O
on	IN	on	on	on	N	O
pooled	VBN	pooled	pooled	pool	N	O
data	NN	data	data	data	N	O
from	IN	from	from	from	N	O
three	CD	three	three	three	N	O
placebo	NN	placebo	placebo	placebo	N	O
-	:	-	-	-	N	O
controlled	VBN	controlled	controlled	control	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
conducted	VBN	conducted	conducted	conduct	N	O
in	IN	in	in	in	N	O
353	CD	353	353	353	N	O
patients	NNS	patients	patient	patient	N	O
6	CD	6	6	6	N	O
years	NNS	years	year	year	N	O
of	IN	of	of	of	N	O
age	NN	age	age	age	N	O
and	CC	and	and	and	N	O
older	JJR	older	older	older	N	O
with	IN	with	with	with	N	O
CF	NNP	cf	cf	cf	N	O
who	WP	who	who	who	N	O
had	VBD	had	had	had	N	O
a	DT	a	a	a	N	O
G551D	NNP	g551d	g551d	g551d	N	O
mutation	NN	mutation	mutation	mutat	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
CFTR	NNP	cftr	cftr	cftr	N	O
gene	NN	gene	gene	gene	N	O
(	(	(	(	(	N	O
Trials	NNS	trials	trial	trial	N	O
1	CD	1	1	1	N	O
and	CC	and	and	and	N	O
2	CD	2	2	2	N	O
)	)	)	)	)	N	O
or	CC	or	or	or	N	O
were	VBD	were	were	were	N	O
homozygous	JJ	homozygous	homozygous	homozyg	N	O
for	IN	for	for	for	N	O
the	DT	the	the	the	N	O
F508del	NNP	f508del	f508del	f508del	N	O
mutation	NN	mutation	mutation	mutat	N	O
(	(	(	(	(	N	O
Trial	JJ	trial	trial	trial	N	O
3	CD	3	3	3	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
addition	NN	addition	addition	addit	N	O
,	,	,	,	,	N	O
the	DT	the	the	the	N	O
following	JJ	following	following	follow	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
have	VBP	have	have	have	N	O
also	RB	also	also	also	N	O
been	VBN	been	been	been	N	O
conducted	VBN	conducted	conducted	conduct	N	O
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Clinical	JJ	clinical	clinical	clinic	N	O
Pharmacology	NNP	pharmacology	pharmacology	pharmacolog	N	O
(	(	(	(	(	N	O
12	CD	12	12	12	N	O
)	)	)	)	)	N	O
and	CC	and	and	and	N	O
Clinical	JJ	clinical	clinical	clinic	N	O
Studies	NNP	studies	study	studi	N	O
(	(	(	(	(	N	O
14	CD	14	14	14	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O
:	:	:	:	:	N	O

An	DT	an	an	an	N	O
8	CD	8	8	8	N	O
-	:	-	-	-	N	O
week	NN	week	week	week	N	O
crossover	NN	crossover	crossover	crossov	N	O
design	NN	design	design	design	N	O
trial	NN	trial	trial	trial	N	O
(	(	(	(	(	N	O
Trial	JJ	trial	trial	trial	N	O
4	CD	4	4	4	N	O
)	)	)	)	)	N	O
involving	VBG	involving	involving	involv	N	O
39	CD	39	39	39	N	O
patients	NNS	patients	patient	patient	N	O
between	IN	between	between	between	N	O
the	DT	the	the	the	N	O
ages	NNS	ages	age	age	N	O
of	IN	of	of	of	N	O
6	CD	6	6	6	N	O
and	CC	and	and	and	N	O
57	CD	57	57	57	N	O
years	NNS	years	year	year	N	O
with	IN	with	with	with	N	O
a	DT	a	a	a	N	O
G1244E	NNP	g1244e	g1244e	g1244e	N	O
,	,	,	,	,	N	O
G1349D	NNP	g1349d	g1349d	g1349d	N	O
,	,	,	,	,	N	O
G178R	NNP	g178r	g178r	g178r	N	O
,	,	,	,	,	N	O
G551S	NNP	g551s	g551s	g551	N	O
,	,	,	,	,	N	O
G970R	NNP	g970r	g970r	g970r	N	O
,	,	,	,	,	N	O
S1251N	NNP	s1251n	s1251n	s1251n	N	O
,	,	,	,	,	N	O
S1255P	NNP	s1255p	s1255p	s1255p	N	O
,	,	,	,	,	N	O
S549N	NNP	s549n	s549n	s549n	N	O
,	,	,	,	,	N	O
or	CC	or	or	or	N	O
S549R	NNP	s549r	s549r	s549r	N	O
mutation	NN	mutation	mutation	mutat	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
CFTR	NNP	cftr	cftr	cftr	N	O
gene	NN	gene	gene	gene	N	O
.	.	.	.	.	N	O

A	DT	a	a	a	N	O
24	CD	24	24	24	N	O
-	:	-	-	-	N	O
week	NN	week	week	week	N	O
placebo	NN	placebo	placebo	placebo	N	O
-	:	-	-	-	N	O
controlled	VBN	controlled	controlled	control	N	O
trial	NN	trial	trial	trial	N	O
(	(	(	(	(	N	O
Trial	JJ	trial	trial	trial	N	O
5	CD	5	5	5	N	O
)	)	)	)	)	N	O
involving	VBG	involving	involving	involv	N	O
69	CD	69	69	69	N	O
patients	NNS	patients	patient	patient	N	O
between	IN	between	between	between	N	O
the	DT	the	the	the	N	O
ages	NNS	ages	age	age	N	O
of	IN	of	of	of	N	O
6	CD	6	6	6	N	O
and	CC	and	and	and	N	O
68	CD	68	68	68	N	O
years	NNS	years	year	year	N	O
with	IN	with	with	with	N	O
an	DT	an	an	an	N	O
R117H	NNP	r117h	r117h	r117h	N	O
mutation	NN	mutation	mutation	mutat	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
CFTR	NNP	cftr	cftr	cftr	N	O
gene	NN	gene	gene	gene	N	O
.	.	.	.	.	N	O

A	DT	a	a	a	N	O
24	CD	24	24	24	N	O
-	:	-	-	-	N	O
week	NN	week	week	week	N	O
open	JJ	open	open	open	N	O
-	:	-	-	-	N	O
label	NN	label	label	label	N	O
trial	NN	trial	trial	trial	N	O
(	(	(	(	(	N	O
Trial	JJ	trial	trial	trial	N	O
6	CD	6	6	6	N	O
)	)	)	)	)	N	O
in	IN	in	in	in	N	O
34	CD	34	34	34	N	O
patients	NNS	patients	patient	patient	N	O
2	CD	2	2	2	N	O
to	TO	to	to	to	N	O
less	JJR	less	le	less	N	O
than	IN	than	than	than	N	O
6	CD	6	6	6	N	O
years	NNS	years	year	year	N	O
of	IN	of	of	of	N	O
age	NN	age	age	age	N	O
.	.	.	.	.	N	O

Patients	NNS	patients	patient	patient	N	O
eligible	JJ	eligible	eligible	elig	N	O
for	IN	for	for	for	N	O
Trial	JJ	trial	trial	trial	N	O
6	CD	6	6	6	N	O
were	VBD	were	were	were	N	O
those	DT	those	those	those	N	O
with	IN	with	with	with	N	O
the	DT	the	the	the	N	O
G551D	NNP	g551d	g551d	g551d	N	O
,	,	,	,	,	N	O
G1244E	NNP	g1244e	g1244e	g1244e	N	O
,	,	,	,	,	N	O
G1349D	NNP	g1349d	g1349d	g1349d	N	O
,	,	,	,	,	N	O
G178R	NNP	g178r	g178r	g178r	N	O
,	,	,	,	,	N	O
G551S	NNP	g551s	g551s	g551	N	O
,	,	,	,	,	N	O
G970R	NNP	g970r	g970r	g970r	N	O
,	,	,	,	,	N	O
S1251N	NNP	s1251n	s1251n	s1251n	N	O
,	,	,	,	,	N	O
S1255P	NNP	s1255p	s1255p	s1255p	N	O
,	,	,	,	,	N	O
S549N	NNP	s549n	s549n	s549n	N	O
,	,	,	,	,	N	O
or	CC	or	or	or	N	O
S549R	NNP	s549r	s549r	s549r	N	O
mutation	NN	mutation	mutation	mutat	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
CFTR	NNP	cftr	cftr	cftr	N	O
gene	NN	gene	gene	gene	N	O
.	.	.	.	.	N	O

Of	IN	of	of	of	N	O
34	CD	34	34	34	N	O
patients	NNS	patients	patient	patient	N	O
enrolled	VBD	enrolled	enrolled	enrol	N	O
,	,	,	,	,	N	O
32	CD	32	32	32	N	O
had	VBD	had	had	had	N	O
the	DT	the	the	the	N	O
G551D	NNP	g551d	g551d	g551d	N	O
mutation	NN	mutation	mutation	mutat	N	O
and	CC	and	and	and	N	O
2	CD	2	2	2	N	O
had	VBD	had	had	had	N	O
the	DT	the	the	the	N	O
S549N	NNP	s549n	s549n	s549n	N	O
mutation	NN	mutation	mutation	mutat	N	O
.	.	.	.	.	N	O

Of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
353	CD	353	353	353	N	O
patients	NNS	patients	patient	patient	N	O
included	VBN	included	included	includ	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
pooled	JJ	pooled	pooled	pool	N	O
analyses	NNS	analyses	analysis	analys	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
CF	NNP	cf	cf	cf	N	O
who	WP	who	who	who	N	O
had	VBD	had	had	had	N	O
either	CC	either	either	either	N	O
a	DT	a	a	a	N	O
G551D	NNP	g551d	g551d	g551d	N	O
mutation	NN	mutation	mutation	mutat	N	O
or	CC	or	or	or	N	O
were	VBD	were	were	were	N	O
homozygous	JJ	homozygous	homozygous	homozyg	N	O
for	IN	for	for	for	N	O
the	DT	the	the	the	N	O
F508del	NNP	f508del	f508del	f508del	N	O
mutation	NN	mutation	mutation	mutat	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
CFTR	NNP	cftr	cftr	cftr	N	O
gene	NN	gene	gene	gene	N	O
,	,	,	,	,	N	O
50%	CD	50%	50%	50%	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
were	VBD	were	were	were	N	O
female	JJ	female	female	femal	N	O
and	CC	and	and	and	N	O
97%	CD	97%	97%	97%	N	O
were	VBD	were	were	were	N	O
Caucasian	NNP	caucasian	caucasian	caucasian	N	O
;	:	;	;	;	N	O
221	CD	221	221	221	N	O
received	VBD	received	received	receiv	N	O
KALYDECO	NNP	kalydeco	kalydeco	kalydeco	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
132	CD	132	132	132	N	O
received	VBD	received	received	receiv	N	O
placebo	NN	placebo	placebo	placebo	N	O
from	IN	from	from	from	N	O
16	CD	16	16	16	N	O
to	TO	to	to	to	N	O
48	CD	48	48	48	N	O
weeks	NNS	weeks	week	week	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O

proportion	NN	proportion	proportion	proport	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
who	WP	who	who	who	N	O
prematurely	RB	prematurely	prematurely	prematur	N	O
discontinued	VBN	discontinued	discontinued	discontinu	N	O
study	JJ	study	study	studi	N	O
drug	NN	drug	drug	drug	N	O
due	JJ	due	due	due	N	O
to	TO	to	to	to	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
was	VBD	was	wa	wa	N	O
2%	CD	2%	2%	2%	N	O
for	IN	for	for	for	N	O
KALYDECO	NNP	kalydeco	kalydeco	kalydeco	N	O
-	:	-	-	-	N	O
treated	VBD	treated	treated	treat	N	O
patients	NNS	patients	patient	patient	N	O
and	CC	and	and	and	N	O
5%	CD	5%	5%	5%	N	O
for	IN	for	for	for	N	O
placebo	NN	placebo	placebo	placebo	N	O
-	:	-	-	-	N	O
treated	JJ	treated	treated	treat	N	O
patients	NNS	patients	patient	patient	N	O
.	.	.	.	.	N	O

Serious	JJ	serious	serious	seriou	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
,	,	,	,	,	N	O
whether	IN	whether	whether	whether	N	O
considered	VBN	considered	considered	consid	N	O
drug	NN	drug	drug	drug	N	O
-	:	-	-	-	N	O
related	VBN	related	related	relat	N	O
or	CC	or	or	or	N	O
not	RB	not	not	not	N	O
by	IN	by	by	by	N	O
the	DT	the	the	the	N	O
investigators	NNS	investigators	investigator	investig	N	O
,	,	,	,	,	N	O
that	WDT	that	that	that	N	O
occurred	VBD	occurred	occurred	occur	N	O
more	RBR	more	more	more	N	O
frequently	RB	frequently	frequently	frequent	N	O
in	IN	in	in	in	N	O
KALYDECO	NNP	kalydeco	kalydeco	kalydeco	N	O
-	:	-	-	-	N	O
treated	VBD	treated	treated	treat	N	O
patients	NNS	patients	patient	patient	N	O
included	VBD	included	included	includ	N	O
abdominal	JJ	abdominal	abdominal	abdomin	N	B-AdverseReaction
pain	NN	pain	pain	pain	Y	I-AdverseReaction
,	,	,	,	,	N	O
increased	VBD	increased	increased	increas	N	B-AdverseReaction
hepatic	JJ	hepatic	hepatic	hepat	N	I-AdverseReaction
enzymes	NNS	enzymes	enzyme	enzym	N	I-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
hypoglycemia	NN	hypoglycemia	hypoglycemia	hypoglycemia	Y	B-AdverseReaction
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
most	RBS	most	most	most	N	O
common	JJ	common	common	common	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
221	CD	221	221	221	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
KALYDECO	NNP	kalydeco	kalydeco	kalydeco	N	O
were	VBD	were	were	were	N	O
headache	NN	headache	headache	headach	Y	B-AdverseReaction
(	(	(	(	(	N	O
17%	CD	17%	17%	17%	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
upper	JJ	upper	upper	upper	N	B-AdverseReaction
respiratory	NN	respiratory	respiratory	respiratori	N	I-AdverseReaction
tract	NN	tract	tract	tract	N	I-AdverseReaction
infection	NN	infection	infection	infect	Y	I-AdverseReaction
(	(	(	(	(	N	O
16%	CD	16%	16%	16%	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
nasal	JJ	nasal	nasal	nasal	N	B-AdverseReaction
congestion	NN	congestion	congestion	congest	N	I-AdverseReaction
(	(	(	(	(	N	O
16%	CD	16%	16%	16%	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
nausea	NN	nausea	nausea	nausea	Y	B-AdverseReaction
(	(	(	(	(	N	O
10%	CD	10%	10%	10%	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
rash	NN	rash	rash	rash	Y	B-AdverseReaction
(	(	(	(	(	N	O
10%	CD	10%	10%	10%	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
rhinitis	NN	rhinitis	rhinitis	rhiniti	Y	B-AdverseReaction
(	(	(	(	(	N	O
6%	CD	6%	6%	6%	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
dizziness	NN	dizziness	dizziness	dizzi	Y	B-AdverseReaction
(	(	(	(	(	N	O
5%	CD	5%	5%	5%	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
arthralgia	RB	arthralgia	arthralgia	arthralgia	Y	B-AdverseReaction
(	(	(	(	(	N	O
5%	CD	5%	5%	5%	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
bacteria	NNS	bacteria	bacteria	bacteria	N	B-AdverseReaction
in	IN	in	in	in	N	I-AdverseReaction
sputum	NN	sputum	sputum	sputum	Y	I-AdverseReaction
(	(	(	(	(	N	O
5%	CD	5%	5%	5%	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
incidence	NN	incidence	incidence	incid	N	O
of	IN	of	of	of	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
below	IN	below	below	below	N	O
is	VBZ	is	is	is	N	O
based	VBN	based	based	base	N	O
upon	IN	upon	upon	upon	N	O
two	CD	two	two	two	N	O
double	JJ	double	double	doubl	N	O
-	:	-	-	-	N	O
blind	NN	blind	blind	blind	Y	O
,	,	,	,	,	N	O
placebo	SYM	placebo	placebo	placebo	N	O
-	:	-	-	-	N	O
controlled	VBN	controlled	controlled	control	N	O
,	,	,	,	,	N	O
48	CD	48	48	48	N	O
-	:	-	-	-	N	O
week	NN	week	week	week	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
(	(	(	(	(	N	O
Trials	NNS	trials	trial	trial	N	O
1	CD	1	1	1	N	O
and	CC	and	and	and	N	O
2	CD	2	2	2	N	O
)	)	)	)	)	N	O
in	IN	in	in	in	N	O
a	DT	a	a	a	N	O
total	NN	total	total	total	N	O
of	IN	of	of	of	N	O
213	CD	213	213	213	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
CF	NNP	cf	cf	cf	N	O
ages	VBZ	ages	age	age	N	O
6	CD	6	6	6	N	O
to	TO	to	to	to	N	O
53	CD	53	53	53	N	O
who	WP	who	who	who	N	O
have	VBP	have	have	have	N	O
a	DT	a	a	a	N	O
G551D	NNP	g551d	g551d	g551d	N	O
mutation	NN	mutation	mutation	mutat	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
CFTR	NNP	cftr	cftr	cftr	N	O
gene	NN	gene	gene	gene	N	O
and	CC	and	and	and	N	O
who	WP	who	who	who	N	O
were	VBD	were	were	were	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
KALYDECO	NNP	kalydeco	kalydeco	kalydeco	N	O
150	CD	150	150	150	N	O
mg	NN	mg	mg	mg	N	O
orally	RB	orally	orally	oral	N	O
or	CC	or	or	or	N	O
placebo	VB	placebo	placebo	placebo	N	O
twice	JJ	twice	twice	twice	N	O
daily	RB	daily	daily	daili	N	O
.	.	.	.	.	N	O

Table	JJ	table	table	tabl	N	O
2	CD	2	2	2	N	O
shows	NNS	shows	show	show	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
occurring	VBG	occurring	occurring	occur	N	O
in	IN	in	in	in	N	O
8%	CD	8%	8%	8%	N	O
of	IN	of	of	of	N	O
KALYDECO	NNP	kalydeco	kalydeco	kalydeco	N	O
-	:	-	-	-	N	O
treated	VBD	treated	treated	treat	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
CF	NNP	cf	cf	cf	N	O
who	WP	who	who	who	N	O
have	VBP	have	have	have	N	O
a	DT	a	a	a	N	O
G551D	NNP	g551d	g551d	g551d	N	O
mutation	NN	mutation	mutation	mutat	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
CFTR	NNP	cftr	cftr	cftr	N	O
gene	NN	gene	gene	gene	N	O
that	WDT	that	that	that	N	O
also	RB	also	also	also	N	O
occurred	VBD	occurred	occurred	occur	N	O
at	IN	at	at	at	N	O
a	DT	a	a	a	N	O
higher	JJR	higher	higher	higher	N	O
rate	NN	rate	rate	rate	N	O
than	IN	than	than	than	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
placebo	NN	placebo	placebo	placebo	N	O
-	:	-	-	-	N	O
treated	JJ	treated	treated	treat	N	O
patients	NNS	patients	patient	patient	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
two	CD	two	two	two	N	O
double	JJ	double	double	doubl	N	O
-	:	-	-	-	N	O
blind	NN	blind	blind	blind	Y	O
,	,	,	,	,	N	O
placebo	SYM	placebo	placebo	placebo	N	O
-	:	-	-	-	N	O
controlled	VBN	controlled	controlled	control	N	O
trials	NNS	trials	trial	trial	N	O
.	.	.	.	.	N	O

Table	JJ	table	table	tabl	N	O
2	CD	2	2	2	N	O
:	:	:	:	:	N	O
Incidence	NN	incidence	incidence	incid	N	O
of	IN	of	of	of	N	O
Adverse	NNP	adverse	adverse	advers	N	O
Drug	NNP	drug	drug	drug	N	O
Reactions	NNP	reactions	reaction	reaction	N	O
in	IN	in	in	in	N	O
8%	CD	8%	8%	8%	N	O
of	IN	of	of	of	N	O
KALYDECO	NNP	kalydeco	kalydeco	kalydeco	N	O
-	:	-	-	-	N	O
Treated	VBD	treated	treated	treat	N	O
Patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
a	DT	a	a	a	N	O
G551D	NNP	g551d	g551d	g551d	N	O
Mutation	NNP	mutation	mutation	mutat	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
CFTR	NNP	cftr	cftr	cftr	N	O
Gene	NNP	gene	gene	gene	N	O
and	CC	and	and	and	N	O
Greater	NNP	greater	greater	greater	N	O
than	IN	than	than	than	N	O
Placebo	NNP	placebo	placebo	placebo	N	O
in	IN	in	in	in	N	O
2	CD	2	2	2	N	O
Placebo	NNP	placebo	placebo	placebo	N	O
-	:	-	-	-	N	O
Controlled	VBD	controlled	controlled	control	N	O
Phase	NNP	phase	phase	phase	N	O
3	CD	3	3	3	N	O
Clinical	NNP	clinical	clinical	clinic	N	O
Trials	NNS	trials	trial	trial	N	O
of	IN	of	of	of	N	O
48	CD	48	48	48	N	O
Weeks	NNP	weeks	week	week	N	O
Duration	NN	duration	duration	durat	N	O

Adverse	JJ	adverse	adverse	advers	N	O
Reaction	NNP	reaction	reaction	reaction	N	O
(	(	(	(	(	N	O
Preferred	NNP	preferred	preferred	prefer	N	O
Term	NNP	term	term	term	N	O
)	)	)	)	)	N	O
Incidence	NN	incidence	incidence	incid	N	O
:	:	:	:	:	N	O
Pooled	VBD	pooled	pooled	pool	N	O
48	CD	48	48	48	N	O
-	:	-	-	-	N	O
Week	NN	week	week	week	N	O
Trials	NNS	trials	trial	trial	N	O

KALYDECON	NNP	kalydecon	kalydecon	kalydecon	N	O
109	CD	109	109	109	N	O
n	NN	n	n	n	N	O
(	(	(	(	(	N	O
)	)	)	)	)	N	O
PlaceboN	VBZ	placebon	placebon	placebon	N	O
104	CD	104	104	104	N	O
n	NN	n	n	n	N	O
(	(	(	(	(	N	O
)	)	)	)	)	N	O

Headache	NN	headache	headache	headach	Y	B-AdverseReaction

26	CD	26	26	26	N	O
(	(	(	(	(	N	O
24	CD	24	24	24	N	O
)	)	)	)	)	N	O
17	CD	17	17	17	N	O
(	(	(	(	(	N	O
16	CD	16	16	16	N	O
)	)	)	)	)	N	O

Oropharyngeal	NNP	oropharyngeal	oropharyngeal	oropharyng	N	B-AdverseReaction
pain	NN	pain	pain	pain	Y	I-AdverseReaction
24	CD	24	24	24	N	O
(	(	(	(	(	N	O
22	CD	22	22	22	N	O
)	)	)	)	)	N	O
19	CD	19	19	19	N	O
(	(	(	(	(	N	O
18	CD	18	18	18	N	O
)	)	)	)	)	N	O

Upper	NNP	upper	upper	upper	N	B-AdverseReaction
respiratory	NN	respiratory	respiratory	respiratori	N	I-AdverseReaction
tract	NN	tract	tract	tract	N	I-AdverseReaction
infection	NN	infection	infection	infect	Y	I-AdverseReaction
24	CD	24	24	24	N	O
(	(	(	(	(	N	O
22	CD	22	22	22	N	O
)	)	)	)	)	N	O
14	CD	14	14	14	N	O
(	(	(	(	(	N	O
14	CD	14	14	14	N	O
)	)	)	)	)	N	O

Nasal	NNP	nasal	nasal	nasal	N	B-AdverseReaction
congestion	NN	congestion	congestion	congest	N	I-AdverseReaction
22	CD	22	22	22	N	O
(	(	(	(	(	N	O
20	CD	20	20	20	N	O
)	)	)	)	)	N	O
16	CD	16	16	16	N	O
(	(	(	(	(	N	O
15	CD	15	15	15	N	O
)	)	)	)	)	N	O

Abdominal	NNP	abdominal	abdominal	abdomin	N	B-AdverseReaction
pain	NN	pain	pain	pain	Y	I-AdverseReaction
17	CD	17	17	17	N	O
(	(	(	(	(	N	O
16	CD	16	16	16	N	O
)	)	)	)	)	N	O
13	CD	13	13	13	N	O
(	(	(	(	(	N	O
13	CD	13	13	13	N	O
)	)	)	)	)	N	O

Nasopharyngitis	RB	nasopharyngitis	nasopharyngitis	nasopharyng	Y	B-AdverseReaction
16	CD	16	16	16	N	O
(	(	(	(	(	N	O
15	CD	15	15	15	N	O
)	)	)	)	)	N	O
12	CD	12	12	12	N	O
(	(	(	(	(	N	O
12	CD	12	12	12	N	O
)	)	)	)	)	N	O

Diarrhea	NNP	diarrhea	diarrhea	diarrhea	Y	B-AdverseReaction
14	CD	14	14	14	N	O
(	(	(	(	(	N	O
13	CD	13	13	13	N	O
)	)	)	)	)	N	O
10	CD	10	10	10	N	O
(	(	(	(	(	N	O
10	CD	10	10	10	N	O
)	)	)	)	)	N	O

Rash	NNP	rash	rash	rash	Y	B-AdverseReaction
14	CD	14	14	14	N	O
(	(	(	(	(	N	O
13	CD	13	13	13	N	O
)	)	)	)	)	N	O
7	CD	7	7	7	N	O
(	(	(	(	(	N	O
7	CD	7	7	7	N	O
)	)	)	)	)	N	O

Nausea	NN	nausea	nausea	nausea	Y	B-AdverseReaction
13	CD	13	13	13	N	O
(	(	(	(	(	N	O
12	CD	12	12	12	N	O
)	)	)	)	)	N	O
11	CD	11	11	11	N	O
(	(	(	(	(	N	O
11	CD	11	11	11	N	O
)	)	)	)	)	N	O

Dizziness	NN	dizziness	dizziness	dizzi	Y	B-AdverseReaction
10	CD	10	10	10	N	O
(	(	(	(	(	N	O
9	CD	9	9	9	N	O
)	)	)	)	)	N	O
1	CD	1	1	1	N	O
(	(	(	(	(	N	O
1	CD	1	1	1	N	O
)	)	)	)	)	N	O

Adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
48	CD	48	48	48	N	O
-	:	-	-	-	N	O
week	NN	week	week	week	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
that	WDT	that	that	that	N	O
occurred	VBD	occurred	occurred	occur	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
KALYDECO	NNP	kalydeco	kalydeco	kalydeco	N	O
group	NN	group	group	group	N	O
at	IN	at	at	at	N	O
a	DT	a	a	a	N	O
frequency	NN	frequency	frequency	frequenc	N	O
of	IN	of	of	of	N	O
4	CD	4	4	4	N	O
to	TO	to	to	to	N	O
7%	CD	7%	7%	7%	N	O
where	WRB	where	where	where	N	O
rates	NNS	rates	rate	rate	N	O
exceeded	VBD	exceeded	exceeded	exceed	N	O
that	IN	that	that	that	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
placebo	NN	placebo	placebo	placebo	N	O
group	NN	group	group	group	N	O
include	VBP	include	include	includ	N	O
:	:	:	:	:	N	O

Infections	NNS	infections	infection	infect	N	O

and	CC	and	and	and	N	O
infestations	NNS	infestations	infestation	infest	N	O
:	:	:	:	:	N	O
rhinitis	NN	rhinitis	rhinitis	rhiniti	Y	B-AdverseReaction

Investigations	NNS	investigations	investigation	investig	N	O
:	:	:	:	:	N	O
aspartate	JJ	aspartate	aspartate	aspart	N	B-AdverseReaction
aminotransferase	NN	aminotransferase	aminotransferase	aminotransferas	N	I-AdverseReaction
increased	VBD	increased	increased	increas	N	I-AdverseReaction
,	,	,	,	,	N	O
bacteria	NNS	bacteria	bacteria	bacteria	N	B-AdverseReaction
in	IN	in	in	in	N	I-AdverseReaction
sputum	NN	sputum	sputum	sputum	Y	I-AdverseReaction
,	,	,	,	,	N	O
blood	NN	blood	blood	blood	N	B-AdverseReaction
glucose	NN	glucose	glucose	glucos	Y	I-AdverseReaction
increased	VBD	increased	increased	increas	N	I-AdverseReaction
,	,	,	,	,	N	O
hepatic	JJ	hepatic	hepatic	hepat	N	B-AdverseReaction
enzyme	NN	enzyme	enzyme	enzym	N	I-AdverseReaction
increased	VBD	increased	increased	increas	N	I-AdverseReaction

Musculoskeletal	NNP	musculoskeletal	musculoskeletal	musculoskelet	N	O
and	CC	and	and	and	N	O
connective	JJ	connective	connective	connect	N	O
tissue	NN	tissue	tissue	tissu	N	O
disorders	NNS	disorders	disorder	disord	N	O
:	:	:	:	:	N	O
arthralgia	NN	arthralgia	arthralgia	arthralgia	Y	B-AdverseReaction
,	,	,	,	,	N	O
musculoskeletal	JJ	musculoskeletal	musculoskeletal	musculoskelet	N	B-AdverseReaction
chest	NN	chest	chest	chest	N	I-AdverseReaction
pain	NN	pain	pain	pain	Y	I-AdverseReaction
,	,	,	,	,	N	O
myalgia	NN	myalgia	myalgia	myalgia	Y	B-AdverseReaction

Nervous	JJ	nervous	nervous	nervou	Y	O
system	NN	system	system	system	N	O
disorders	NNS	disorders	disorder	disord	N	O
:	:	:	:	:	N	O
sinus	NN	sinus	sinus	sinu	N	B-AdverseReaction
headache	NN	headache	headache	headach	Y	I-AdverseReaction

Respiratory	NNP	respiratory	respiratory	respiratori	N	O
,	,	,	,	,	N	O
thoracic	NN	thoracic	thoracic	thorac	N	O
and	CC	and	and	and	N	O
mediastinal	JJ	mediastinal	mediastinal	mediastin	N	O
disorders	NNS	disorders	disorder	disord	N	O
:	:	:	:	:	N	O
pharyngeal	NN	pharyngeal	pharyngeal	pharyng	N	B-AdverseReaction
erythema	NN	erythema	erythema	erythema	Y	I-AdverseReaction
,	,	,	,	,	N	O
pleuritic	JJ	pleuritic	pleuritic	pleurit	N	B-AdverseReaction
pain	NN	pain	pain	pain	Y	I-AdverseReaction
,	,	,	,	,	N	O
sinus	NN	sinus	sinus	sinu	N	B-AdverseReaction
congestion	NN	congestion	congestion	congest	N	I-AdverseReaction
,	,	,	,	,	N	O
wheezing	VBG	wheezing	wheezing	wheez	Y	B-AdverseReaction

Skin	NNP	skin	skin	skin	N	O
and	CC	and	and	and	N	O
subcutaneous	JJ	subcutaneous	subcutaneous	subcutan	N	O
tissue	NN	tissue	tissue	tissu	N	O
disorders	NNS	disorders	disorder	disord	N	O
:	:	:	:	:	N	O
acne	NN	acne	acne	acn	Y	B-AdverseReaction

The	DT	the	the	the	N	O
safety	NN	safety	safety	safeti	N	O
profile	NN	profile	profile	profil	N	O
for	IN	for	for	for	N	O
the	DT	the	the	the	N	O
CF	NNP	cf	cf	cf	N	O
patients	NNS	patients	patient	patient	N	O
enrolled	VBD	enrolled	enrolled	enrol	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
other	JJ	other	other	other	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
(	(	(	(	(	N	O
Trials	NNS	trials	trial	trial	N	O
3	CD	3	3	3	N	O
-	:	-	-	-	N	O
6	CD	6	6	6	N	O
)	)	)	)	)	N	O
was	VBD	was	wa	wa	N	O
similar	JJ	similar	similar	similar	N	O
to	TO	to	to	to	N	O
that	DT	that	that	that	N	O
observed	VBN	observed	observed	observ	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
48	CD	48	48	48	N	O
-	:	-	-	-	N	O
week	NN	week	week	week	N	O
,	,	,	,	,	N	O
placebo	SYM	placebo	placebo	placebo	N	O
-	:	-	-	-	N	O
controlled	VBN	controlled	controlled	control	N	O
trials	NNS	trials	trial	trial	N	O
(	(	(	(	(	N	O
Trials	NNS	trials	trial	trial	N	O
1	CD	1	1	1	N	O
and	CC	and	and	and	N	O
2	CD	2	2	2	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

Laboratory	NN	laboratory	laboratory	laboratori	N	O

Abnormalities	NNS	abnormalities	abnormality	abnorm	N	O

Transaminase	NNP	transaminase	transaminase	transaminas	N	O
Elevations	NNS	elevations	elevation	elev	N	O
:	:	:	:	:	N	O
In	IN	in	in	in	N	O
Trials	NNS	trials	trial	trial	N	O
1	CD	1	1	1	N	O
,	,	,	,	,	N	O
2	CD	2	2	2	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
3	CD	3	3	3	N	O
the	DT	the	the	the	N	O
incidence	NN	incidence	incidence	incid	N	O
of	IN	of	of	of	N	O
maximum	JJ	maximum	maximum	maximum	N	O
transaminase	NN	transaminase	transaminase	transaminas	N	B-AdverseReaction
(	(	(	(	(	N	O
ALT	NNP	alt	alt	alt	N	B-AdverseReaction
or	CC	or	or	or	N	O
AST	NNP	ast	ast	ast	N	B-AdverseReaction
)	)	)	)	)	N	O
8	CD	8	8	8	N	I-AdverseReaction
,	,	,	,	,	N	O
5	CD	5	5	5	N	I-AdverseReaction
,	,	,	,	,	N	O
or	CC	or	or	or	N	O
3	CD	3	3	3	N	I-AdverseReaction
ULN	NNP	uln	uln	uln	N	I-AdverseReaction
was	VBD	was	wa	wa	N	O
2%	CD	2%	2%	2%	N	O
,	,	,	,	,	N	O
2%	CD	2%	2%	2%	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
6%	CD	6%	6%	6%	N	O
in	IN	in	in	in	N	O
KALYDECO	NNP	kalydeco	kalydeco	kalydeco	N	O
-	:	-	-	-	N	O
treated	VBD	treated	treated	treat	N	O
patients	NNS	patients	patient	patient	N	O
and	CC	and	and	and	N	O
2%	CD	2%	2%	2%	N	O
,	,	,	,	,	N	O
2%	CD	2%	2%	2%	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
8%	CD	8%	8%	8%	N	O
in	IN	in	in	in	N	O
placebo	NN	placebo	placebo	placebo	N	O
-	:	-	-	-	N	O
treated	JJ	treated	treated	treat	N	O
patients	NNS	patients	patient	patient	N	O
,	,	,	,	,	N	O
respectively	RB	respectively	respectively	respect	N	O
.	.	.	.	.	N	O

Two	CD	two	two	two	N	O
patients	NNS	patients	patient	patient	N	O
(	(	(	(	(	N	O
2%	CD	2%	2%	2%	N	O
)	)	)	)	)	N	O
on	IN	on	on	on	N	O
placebo	NN	placebo	placebo	placebo	N	O
and	CC	and	and	and	N	O
1	CD	1	1	1	N	O
patient	NN	patient	patient	patient	N	O
(	(	(	(	(	N	O
0.5%	CD	0.5%	0.5%	0.5%	N	O
)	)	)	)	)	N	O
on	IN	on	on	on	N	O
KALYDECO	NNP	kalydeco	kalydeco	kalydeco	N	O
permanently	RB	permanently	permanently	perman	N	O
discontinued	VBD	discontinued	discontinued	discontinu	N	O
treatment	NN	treatment	treatment	treatment	N	O
for	IN	for	for	for	N	O
elevated	JJ	elevated	elevated	elev	N	B-AdverseReaction
transaminases	NNS	transaminases	transaminase	transaminas	Y	I-AdverseReaction
,	,	,	,	,	N	O
all	DT	all	all	all	N	O
8	CD	8	8	8	N	B-Severity
ULN	NNP	uln	uln	uln	N	I-Severity
.	.	.	.	.	N	O

Two	CD	two	two	two	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
KALYDECO	NNP	kalydeco	kalydeco	kalydeco	N	O
were	VBD	were	were	were	N	O
reported	VBN	reported	reported	report	N	O
to	TO	to	to	to	N	O
have	VB	have	have	have	N	O
serious	JJ	serious	serious	seriou	N	B-Severity
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
of	IN	of	of	of	N	O
elevated	VBN	elevated	elevated	elev	N	B-AdverseReaction
liver	NN	liver	liver	liver	N	I-AdverseReaction
transaminases	NNS	transaminases	transaminase	transaminas	Y	I-AdverseReaction
compared	VBN	compared	compared	compar	N	O
to	TO	to	to	to	N	O
none	NN	none	none	none	N	O
on	IN	on	on	on	N	O
placebo	NN	placebo	placebo	placebo	N	O
.	.	.	.	.	N	O

Transaminase	NNP	transaminase	transaminase	transaminas	N	O
elevations	NNS	elevations	elevation	elev	N	O
were	VBD	were	were	were	N	O
more	JJR	more	more	more	N	O
common	JJ	common	common	common	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
a	DT	a	a	a	N	O
history	NN	history	history	histori	N	O
of	IN	of	of	of	N	O
transaminase	NN	transaminase	transaminase	transaminas	N	O
elevations	NNS	elevations	elevation	elev	N	O
[	VBP	[	[	[	N	O
see	VBP	see	see	see	N	O
Warnings	NNS	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.1	CD	5.1	5.1	5.1	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O
.	.	.	.	.	N	O

During	IN	during	during	dure	N	O
the	DT	the	the	the	N	O
24	CD	24	24	24	N	O
-	:	-	-	-	N	O
week	NN	week	week	week	N	O
,	,	,	,	,	N	O
open	JJ	open	open	open	N	O
-	:	-	-	-	N	O
label	NN	label	label	label	N	O
,	,	,	,	,	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trial	NN	trial	trial	trial	N	O
in	IN	in	in	in	N	O
34	CD	34	34	34	N	O
patients	NNS	patients	patient	patient	N	O
ages	VBZ	ages	age	age	N	O
2	CD	2	2	2	N	O
to	TO	to	to	to	N	O
less	JJR	less	le	less	N	O
than	IN	than	than	than	N	O
6	CD	6	6	6	N	O
years	NNS	years	year	year	N	O
(	(	(	(	(	N	O
Trial	JJ	trial	trial	trial	N	O
6	CD	6	6	6	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
where	WRB	where	where	where	N	O
patients	NNS	patients	patient	patient	N	O
received	VBD	received	received	receiv	N	O
either	RB	either	either	either	N	O
50	CD	50	50	50	N	O
mg	NN	mg	mg	mg	N	O
(	(	(	(	(	N	O
less	JJR	less	le	less	N	O
than	IN	than	than	than	N	O
14	CD	14	14	14	N	O
kg	NN	kg	kg	kg	N	O
)	)	)	)	)	N	O
or	CC	or	or	or	N	O
75	CD	75	75	75	N	O
mg	NN	mg	mg	mg	N	O
(	(	(	(	(	N	O
14	CD	14	14	14	N	O
kg	NN	kg	kg	kg	N	O
or	CC	or	or	or	N	O
greater	JJR	greater	greater	greater	N	O
)	)	)	)	)	N	O
ivacaftor	NN	ivacaftor	ivacaftor	ivacaftor	N	O
granules	NNS	granules	granule	granul	N	O
twice	RB	twice	twice	twice	N	O
daily	RB	daily	daily	daili	N	O
,	,	,	,	,	N	O
the	DT	the	the	the	N	O
incidence	NN	incidence	incidence	incid	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
experiencing	VBG	experiencing	experiencing	experienc	N	O
transaminase	JJ	transaminase	transaminase	transaminas	N	B-AdverseReaction
elevations	NNS	elevations	elevation	elev	N	I-AdverseReaction
(	(	(	(	(	N	O
ALT	NNP	alt	alt	alt	N	B-AdverseReaction
or	CC	or	or	or	N	O
AST	NNP	ast	ast	ast	N	B-AdverseReaction
)	)	)	)	)	N	O
3	CD	3	3	3	N	I-AdverseReaction
ULN	NNP	uln	uln	uln	N	I-AdverseReaction
was	VBD	was	wa	wa	N	O
14.7%	CD	14.7%	14.7%	14.7%	N	O
(	(	(	(	(	N	O
5	CD	5	5	5	N	O
34	CD	34	34	34	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

All	DT	all	all	all	N	O
5	CD	5	5	5	N	O
patients	NNS	patients	patient	patient	N	O
had	VBD	had	had	had	N	O
maximum	JJ	maximum	maximum	maximum	N	O
ALT	NNP	alt	alt	alt	N	B-AdverseReaction
or	CC	or	or	or	N	O
AST	NNP	ast	ast	ast	N	B-AdverseReaction
levels	NNS	levels	level	level	N	I-AdverseReaction
8	CD	8	8	8	N	I-AdverseReaction
ULN	NNP	uln	uln	uln	N	I-AdverseReaction
,	,	,	,	,	N	O
which	WDT	which	which	which	N	O
returned	VBD	returned	returned	return	N	O
to	TO	to	to	to	N	O
baseline	VB	baseline	baseline	baselin	N	O
levels	NNS	levels	level	level	N	O
following	VBG	following	following	follow	N	O
interruption	NN	interruption	interruption	interrupt	N	O
of	IN	of	of	of	N	O
KALYDECO	NNP	kalydeco	kalydeco	kalydeco	N	O
dosing	NN	dosing	dosing	dose	N	O
.	.	.	.	.	N	O

Transaminase	NNP	transaminase	transaminase	transaminas	N	O
elevations	NNS	elevations	elevation	elev	N	O
were	VBD	were	were	were	N	O
more	JJR	more	more	more	N	O
common	JJ	common	common	common	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
who	WP	who	who	who	N	O
had	VBD	had	had	had	N	O
abnormal	JJ	abnormal	abnormal	abnorm	N	O
transaminases	NNS	transaminases	transaminase	transaminas	Y	O
at	IN	at	at	at	N	O
baseline	NN	baseline	baseline	baselin	N	O
.	.	.	.	.	N	O

KALYDECO	NNP	kalydeco	kalydeco	kalydeco	N	O
was	VBD	was	wa	wa	N	O
permanently	RB	permanently	permanently	perman	N	O
discontinued	VBN	discontinued	discontinued	discontinu	N	O
in	IN	in	in	in	N	O
one	CD	one	one	one	N	O
patient	NN	patient	patient	patient	N	O
[	NN	[	[	[	N	O
see	VBP	see	see	see	N	O
Warnings	NNS	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.1	CD	5.1	5.1	5.1	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O
.	.	.	.	.	N	O
5	CD	5	5	5	N	O
WARNINGS	NNP	warnings	warning	warn	N	O
AND	NNP	and	and	and	N	O
PRECAUTIONS	NNP	precautions	precaution	precaut	N	O

EXCERPT	NN	excerpt	excerpt	excerpt	N	O
:	:	:	:	:	N	O
Elevated	VBN	elevated	elevated	elev	N	B-AdverseReaction
transaminases	NNS	transaminases	transaminase	transaminas	Y	I-AdverseReaction
(	(	(	(	(	N	O
ALT	NNP	alt	alt	alt	N	I-AdverseReaction
or	CC	or	or	or	N	O
AST	NNP	ast	ast	ast	N	I-AdverseReaction
)	)	)	)	)	N	O
:	:	:	:	:	N	O
Transaminases	NNS	transaminases	transaminase	transaminas	Y	O
(	(	(	(	(	N	O
ALT	NNP	alt	alt	alt	N	O
and	CC	and	and	and	N	O
AST	NNP	ast	ast	ast	N	O
)	)	)	)	)	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
assessed	VBN	assessed	assessed	assess	N	O
prior	RB	prior	prior	prior	N	O
to	TO	to	to	to	N	O
initiating	VBG	initiating	initiating	initi	N	O
KALYDECO	NNP	kalydeco	kalydeco	kalydeco	N	O
,	,	,	,	,	N	O
every	DT	every	every	everi	N	O
3	CD	3	3	3	N	O
months	NNS	months	month	month	N	O
during	IN	during	during	dure	N	O
the	DT	the	the	the	N	O
first	JJ	first	first	first	N	O
year	NN	year	year	year	N	O
of	IN	of	of	of	N	O
treatment	NN	treatment	treatment	treatment	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
annually	RB	annually	annually	annual	N	O
thereafter	RB	thereafter	thereafter	thereaft	N	O
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
a	DT	a	a	a	N	O
history	NN	history	history	histori	N	O
of	IN	of	of	of	N	O
transaminase	NN	transaminase	transaminase	transaminas	N	O
elevations	NNS	elevations	elevation	elev	N	O
,	,	,	,	,	N	O
more	RBR	more	more	more	N	O
frequent	JJ	frequent	frequent	frequent	N	O
monitoring	NN	monitoring	monitoring	monitor	N	O
of	IN	of	of	of	N	O
liver	JJ	liver	liver	liver	N	O
function	NN	function	function	function	N	O
tests	NNS	tests	test	test	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
considered	VBN	considered	considered	consid	N	O
.	.	.	.	.	N	O

Patients	NNS	patients	patient	patient	N	O
who	WP	who	who	who	N	O
develop	VBP	develop	develop	develop	N	O
increased	VBN	increased	increased	increas	N	O
transaminase	NN	transaminase	transaminase	transaminas	N	O
levels	NNS	levels	level	level	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
closely	RB	closely	closely	close	N	O
monitored	VBN	monitored	monitored	monitor	N	O
until	IN	until	until	until	N	O
the	DT	the	the	the	N	O
abnormalities	NNS	abnormalities	abnormality	abnorm	N	O
resolve	VBP	resolve	resolve	resolv	N	O
.	.	.	.	.	N	O

Dosing	VBG	dosing	dosing	dose	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
interrupted	VBN	interrupted	interrupted	interrupt	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
ALT	NNP	alt	alt	alt	N	O
or	CC	or	or	or	N	O
AST	NNP	ast	ast	ast	N	O
of	IN	of	of	of	N	O
greater	JJR	greater	greater	greater	N	O
than	IN	than	than	than	N	O
5	CD	5	5	5	N	O
times	NNS	times	time	time	N	O
the	DT	the	the	the	N	O
upper	JJ	upper	upper	upper	N	O
limit	NN	limit	limit	limit	N	O
of	IN	of	of	of	N	O
normal	JJ	normal	normal	normal	N	O
(	(	(	(	(	N	O
ULN	NNP	uln	uln	uln	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

Following	VBG	following	following	follow	N	O
resolution	NN	resolution	resolution	resolut	N	O
of	IN	of	of	of	N	O
transaminase	NN	transaminase	transaminase	transaminas	N	O
elevations	NNS	elevations	elevation	elev	N	O
,	,	,	,	,	N	O
consider	VB	consider	consider	consid	N	O
the	DT	the	the	the	N	O
benefits	NNS	benefits	benefit	benefit	N	O
and	CC	and	and	and	N	O
risks	NNS	risks	risk	risk	N	O
of	IN	of	of	of	N	O
resuming	VBG	resuming	resuming	resum	N	O
KALYDECO	NNP	kalydeco	kalydeco	kalydeco	N	O
dosing	NN	dosing	dosing	dose	N	O
.	.	.	.	.	N	O

(	(	(	(	(	N	O
5.1	CD	5.1	5.1	5.1	N	O
,	,	,	,	,	N	O
6	CD	6	6	6	N	O
)	)	)	)	)	N	O

Use	NN	use	use	use	N	O
with	IN	with	with	with	N	O
CYP3A	NNP	cyp3a	cyp3a	cyp3a	N	O
inducers	NNS	inducers	inducer	induc	N	O
:	:	:	:	:	N	O
Concomitant	NNP	concomitant	concomitant	concomit	N	O
use	NN	use	use	use	N	O
with	IN	with	with	with	N	O
strong	JJ	strong	strong	strong	N	O
CYP3A	NNP	cyp3a	cyp3a	cyp3a	N	O
inducers	NNS	inducers	inducer	induc	N	O
(	(	(	(	(	N	O
e	NN	e	e	e	N	O
.	.	.	.	.	N	O
g	NN	g	g	g	N	O
.	.	.	.	.	N	O
,	,	,	,	,	N	O
rifampin	NN	rifampin	rifampin	rifampin	N	O
,	,	,	,	,	N	O
St	NNP	st	st	st	N	O
.	.	.	.	.	N	O

John	NNP	john	john	john	N	O
's	POS	's	's	's	N	O
wort	NN	wort	wort	wort	N	O
)	)	)	)	)	N	O
substantially	RB	substantially	substantially	substanti	N	O
decreases	VBZ	decreases	decrease	decreas	N	O
exposure	NN	exposure	exposure	exposur	N	O
of	IN	of	of	of	N	O
ivacaftor	NN	ivacaftor	ivacaftor	ivacaftor	N	O
,	,	,	,	,	N	O
which	WDT	which	which	which	N	O
may	MD	may	may	may	N	O
diminish	VB	diminish	diminish	diminish	N	O
effectiveness	NN	effectiveness	effectiveness	effect	N	O
.	.	.	.	.	N	O

Therefore	RB	therefore	therefore	therefor	N	O
,	,	,	,	,	N	O
co	SYM	co	co	co	N	O
-	:	-	-	-	N	O
administration	NN	administration	administration	administr	N	O
is	VBZ	is	is	is	N	O
not	RB	not	not	not	N	O
recommended	VBN	recommended	recommended	recommend	N	O
.	.	.	.	.	N	O

(	(	(	(	(	N	O
5.2	CD	5.2	5.2	5.2	N	O
,	,	,	,	,	N	O
7.2	CD	7.2	7.2	7.2	N	O
,	,	,	,	,	N	O
12.3	CD	12.3	12.3	12.3	N	O
)	)	)	)	)	N	O

Cataracts	NNS	cataracts	cataract	cataract	Y	B-AdverseReaction
:	:	:	:	:	N	O
Non	NNP	non	non	non	N	B-AdverseReaction
-	:	-	-	-	N	I-AdverseReaction
congenital	NN	congenital	congenital	congenit	N	I-AdverseReaction
lens	VBZ	lens	lens	len	N	I-AdverseReaction
opacities	NNS	opacities	opacity	opac	N	I-AdverseReaction
cataracts	NNS	cataracts	cataract	cataract	Y	I-AdverseReaction
have	VBP	have	have	have	N	O
been	VBN	been	been	been	N	O
reported	VBN	reported	reported	report	N	O
in	IN	in	in	in	N	O
pediatric	JJ	pediatric	pediatric	pediatr	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
KALYDECO	NNP	kalydeco	kalydeco	kalydeco	N	O
.	.	.	.	.	N	O

Baseline	NNP	baseline	baseline	baselin	N	O
and	CC	and	and	and	N	O
follow	VB	follow	follow	follow	N	O
-	:	-	-	-	N	O
up	IN	up	up	up	N	O
examinations	NNS	examinations	examination	examin	N	O
are	VBP	are	are	are	N	O
recommended	VBN	recommended	recommended	recommend	N	O
in	IN	in	in	in	N	O
pediatric	JJ	pediatric	pediatric	pediatr	N	O
patients	NNS	patients	patient	patient	N	O
initiating	VBG	initiating	initiating	initi	N	O
KALYDECO	NNP	kalydeco	kalydeco	kalydeco	N	O
treatment	NN	treatment	treatment	treatment	N	O
.	.	.	.	.	N	O

(	(	(	(	(	N	O
5.3	CD	5.3	5.3	5.3	N	O
)	)	)	)	)	N	O

5.1	CD	5.1	5.1	5.1	N	O

Transaminase	NN	transaminase	transaminase	transaminas	N	O

(	(	(	(	(	N	O
ALT	NNP	alt	alt	alt	N	O
or	CC	or	or	or	N	O
AST	NNP	ast	ast	ast	N	O
)	)	)	)	)	N	O
Elevations	NNS	elevations	elevation	elev	N	O

Elevated	VBN	elevated	elevated	elev	N	B-AdverseReaction
transaminases	NNS	transaminases	transaminase	transaminas	Y	I-AdverseReaction
have	VBP	have	have	have	N	O
been	VBN	been	been	been	N	O
reported	VBN	reported	reported	report	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
CF	NNP	cf	cf	cf	N	O
receiving	VBG	receiving	receiving	receiv	N	O
KALYDECO	NNP	kalydeco	kalydeco	kalydeco	N	O
.	.	.	.	.	N	O

It	PRP	it	it	it	N	O
is	VBZ	is	is	is	N	O
recommended	VBN	recommended	recommended	recommend	N	O
that	IN	that	that	that	N	O
ALT	NNP	alt	alt	alt	N	O
and	CC	and	and	and	N	O
AST	NNP	ast	ast	ast	N	O
be	VB	be	be	be	N	O
assessed	VBN	assessed	assessed	assess	N	O
prior	RB	prior	prior	prior	N	O
to	TO	to	to	to	N	O
initiating	VBG	initiating	initiating	initi	N	O
KALYDECO	NNP	kalydeco	kalydeco	kalydeco	N	O
,	,	,	,	,	N	O
every	DT	every	every	everi	N	O
3	CD	3	3	3	N	O
months	NNS	months	month	month	N	O
during	IN	during	during	dure	N	O
the	DT	the	the	the	N	O
first	JJ	first	first	first	N	O
year	NN	year	year	year	N	O
of	IN	of	of	of	N	O
treatment	NN	treatment	treatment	treatment	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
annually	RB	annually	annually	annual	N	O
thereafter	RB	thereafter	thereafter	thereaft	N	O
.	.	.	.	.	N	O

For	IN	for	for	for	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
a	DT	a	a	a	N	O
history	NN	history	history	histori	N	O
of	IN	of	of	of	N	O
transaminase	NN	transaminase	transaminase	transaminas	N	O
elevations	NNS	elevations	elevation	elev	N	O
,	,	,	,	,	N	O
more	RBR	more	more	more	N	O
frequent	JJ	frequent	frequent	frequent	N	O
monitoring	NN	monitoring	monitoring	monitor	N	O
of	IN	of	of	of	N	O
liver	JJ	liver	liver	liver	N	O
function	NN	function	function	function	N	O
tests	NNS	tests	test	test	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
considered	VBN	considered	considered	consid	N	O
.	.	.	.	.	N	O

Patients	NNS	patients	patient	patient	N	O
who	WP	who	who	who	N	O
develop	VBP	develop	develop	develop	N	O
increased	VBN	increased	increased	increas	N	O
transaminase	NN	transaminase	transaminase	transaminas	N	O
levels	NNS	levels	level	level	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
closely	RB	closely	closely	close	N	O
monitored	VBN	monitored	monitored	monitor	N	O
until	IN	until	until	until	N	O
the	DT	the	the	the	N	O
abnormalities	NNS	abnormalities	abnormality	abnorm	N	O
resolve	VBP	resolve	resolve	resolv	N	O
.	.	.	.	.	N	O

Dosing	VBG	dosing	dosing	dose	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
interrupted	VBN	interrupted	interrupted	interrupt	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
ALT	NNP	alt	alt	alt	N	O
or	CC	or	or	or	N	O
AST	NNP	ast	ast	ast	N	O
of	IN	of	of	of	N	O
greater	JJR	greater	greater	greater	N	O
than	IN	than	than	than	N	O
5	CD	5	5	5	N	O
times	NNS	times	time	time	N	O
the	DT	the	the	the	N	O
upper	JJ	upper	upper	upper	N	O
limit	NN	limit	limit	limit	N	O
of	IN	of	of	of	N	O
normal	JJ	normal	normal	normal	N	O
(	(	(	(	(	N	O
ULN	NNP	uln	uln	uln	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

Following	VBG	following	following	follow	N	O
resolution	NN	resolution	resolution	resolut	N	O
of	IN	of	of	of	N	O
transaminase	NN	transaminase	transaminase	transaminas	N	O
elevations	NNS	elevations	elevation	elev	N	O
,	,	,	,	,	N	O
consider	VB	consider	consider	consid	N	O
the	DT	the	the	the	N	O
benefits	NNS	benefits	benefit	benefit	N	O
and	CC	and	and	and	N	O
risks	NNS	risks	risk	risk	N	O
of	IN	of	of	of	N	O
resuming	VBG	resuming	resuming	resum	N	O
KALYDECO	NNP	kalydeco	kalydeco	kalydeco	N	O
dosing	VBG	dosing	dosing	dose	N	O
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Adverse	JJ	adverse	adverse	advers	N	O
Reactions	NNP	reactions	reaction	reaction	N	O
(	(	(	(	(	N	O
6	CD	6	6	6	N	O
)	)	)	)	)	N	O
and	CC	and	and	and	N	O
Use	NNP	use	use	use	N	O
in	IN	in	in	in	N	O
Specific	NNP	specific	specific	specif	N	O
Populations	NNP	populations	population	popul	N	O
(	(	(	(	(	N	O
8.6	CD	8.6	8.6	8.6	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O
.	.	.	.	.	N	O

5.2	CD	5.2	5.2	5.2	N	O
Concomitant	NNP	concomitant	concomitant	concomit	N	O
Use	NNP	use	use	use	N	O
with	IN	with	with	with	N	O
CYP3A	NNP	cyp3a	cyp3a	cyp3a	N	O
Inducers	NNS	inducers	inducer	induc	N	O

Use	NNP	use	use	use	N	O
of	IN	of	of	of	N	O
KALYDECO	NNP	kalydeco	kalydeco	kalydeco	N	O
with	IN	with	with	with	N	O
strong	JJ	strong	strong	strong	N	O
CYP3A	NNP	cyp3a	cyp3a	cyp3a	N	O
inducers	NNS	inducers	inducer	induc	N	O
,	,	,	,	,	N	O
such	JJ	such	such	such	N	O
as	IN	as	a	as	N	O
rifampin	NN	rifampin	rifampin	rifampin	N	O
,	,	,	,	,	N	O
substantially	RB	substantially	substantially	substanti	N	O
decreases	VBZ	decreases	decrease	decreas	N	O
the	DT	the	the	the	N	O
exposure	NN	exposure	exposure	exposur	N	O
of	IN	of	of	of	N	O
ivacaftor	NN	ivacaftor	ivacaftor	ivacaftor	N	O
,	,	,	,	,	N	O
which	WDT	which	which	which	N	O
may	MD	may	may	may	N	O
reduce	VB	reduce	reduce	reduc	N	O
the	DT	the	the	the	N	O
therapeutic	JJ	therapeutic	therapeutic	therapeut	N	O
effectiveness	NN	effectiveness	effectiveness	effect	N	O
of	IN	of	of	of	N	O
KALYDECO	NNP	kalydeco	kalydeco	kalydeco	N	O
.	.	.	.	.	N	O

Therefore	RB	therefore	therefore	therefor	N	O
,	,	,	,	,	N	O
co	SYM	co	co	co	N	O
-	:	-	-	-	N	O
administration	NN	administration	administration	administr	N	O
of	IN	of	of	of	N	O
KALYDECO	NNP	kalydeco	kalydeco	kalydeco	N	O
with	IN	with	with	with	N	O
strong	JJ	strong	strong	strong	N	O
CYP3A	NNP	cyp3a	cyp3a	cyp3a	N	O
inducers	NNS	inducers	inducer	induc	N	O
(	(	(	(	(	N	O
e	NN	e	e	e	N	O
.	.	.	.	.	N	O
g	NN	g	g	g	N	O
.	.	.	.	.	N	O
,	,	,	,	,	N	O
rifampin	NN	rifampin	rifampin	rifampin	N	O
,	,	,	,	,	N	O
St	NNP	st	st	st	N	O
.	.	.	.	.	N	O

John	NNP	john	john	john	N	O
's	POS	's	's	's	N	O
wort	NN	wort	wort	wort	N	O
)	)	)	)	)	N	O
is	VBZ	is	is	is	N	O
not	RB	not	not	not	N	O
recommended	JJ	recommended	recommended	recommend	N	O
[	NNS	[	[	[	N	O
see	VBP	see	see	see	N	O
Drug	JJ	drug	drug	drug	N	O
Interactions	NNP	interactions	interaction	interact	N	O
(	(	(	(	(	N	O
7.2	CD	7.2	7.2	7.2	N	O
)	)	)	)	)	N	O
and	CC	and	and	and	N	O
Clinical	JJ	clinical	clinical	clinic	N	O
Pharmacology	NNP	pharmacology	pharmacology	pharmacolog	N	O
(	(	(	(	(	N	O
12.3	CD	12.3	12.3	12.3	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O
.	.	.	.	.	N	O

5.3	CD	5.3	5.3	5.3	N	O
Cataracts	NNS	cataracts	cataract	cataract	Y	O

Cases	NNS	cases	case	case	N	O
of	IN	of	of	of	N	O
non	JJ	non	non	non	N	B-AdverseReaction
-	:	-	-	-	N	I-AdverseReaction
congenital	NN	congenital	congenital	congenit	N	I-AdverseReaction
lens	VBZ	lens	lens	len	N	I-AdverseReaction
opacities	NNS	opacities	opacity	opac	N	I-AdverseReaction
cataracts	NNS	cataracts	cataract	cataract	Y	I-AdverseReaction
have	VBP	have	have	have	N	O
been	VBN	been	been	been	N	O
reported	VBN	reported	reported	report	N	O
in	IN	in	in	in	N	O
pediatric	JJ	pediatric	pediatric	pediatr	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
KALYDECO	NNP	kalydeco	kalydeco	kalydeco	N	O
.	.	.	.	.	N	O

Although	IN	although	although	although	N	O
other	JJ	other	other	other	N	O
risk	NN	risk	risk	risk	N	O
factors	NNS	factors	factor	factor	N	O
were	VBD	were	were	were	N	O
present	JJ	present	present	present	N	O
in	IN	in	in	in	N	O
some	DT	some	some	some	N	O
cases	NNS	cases	case	case	N	O
(	(	(	(	(	N	O
such	JJ	such	such	such	N	O
as	IN	as	a	as	N	O
corticosteroid	NN	corticosteroid	corticosteroid	corticosteroid	N	O
use	NN	use	use	use	N	O
and	CC	and	and	and	N	O
or	CC	or	or	or	N	O
exposure	NN	exposure	exposure	exposur	N	O
to	TO	to	to	to	N	O
radiation	NN	radiation	radiation	radiat	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
a	DT	a	a	a	N	O
possible	JJ	possible	possible	possibl	N	O
risk	NN	risk	risk	risk	N	O
attributable	JJ	attributable	attributable	attribut	N	O
to	TO	to	to	to	N	O
KALYDECO	NNP	kalydeco	kalydeco	kalydeco	N	O
cannot	NN	cannot	cannot	cannot	N	O
be	VB	be	be	be	N	O
excluded	VBN	excluded	excluded	exclud	N	O
.	.	.	.	.	N	O

Baseline	NNP	baseline	baseline	baselin	N	O
and	CC	and	and	and	N	O
follow	VB	follow	follow	follow	N	O
-	:	-	-	-	N	O
up	RB	up	up	up	N	O
ophthalmological	JJ	ophthalmological	ophthalmological	ophthalmolog	N	O
examinations	NNS	examinations	examination	examin	N	O
are	VBP	are	are	are	N	O
recommended	VBN	recommended	recommended	recommend	N	O
in	IN	in	in	in	N	O
pediatric	JJ	pediatric	pediatric	pediatr	N	O
patients	NNS	patients	patient	patient	N	O
initiating	VBG	initiating	initiating	initi	N	O
KALYDECO	NNP	kalydeco	kalydeco	kalydeco	N	O
treatment	NN	treatment	treatment	treatment	N	O
.	.	.	.	.	N	O

